Long-term maintenance of disease control in recalcitrant atopic and non-atopic chronic hand or hand-and-foot eczema after dupilumab treatment de-escalation in clinical practice

Key Points

• To evaluate the long-term maintenance of disease control in patients with recalcitrant chronic eczema following dupilumab treatment de-escalation.
• Seven patients with recalcitrant eczema received dupilumab treatment for at least one year.
• Treatment was de-escalated while monitoring disease control and tolerance.
• All seven patients maintained disease control for a minimum of one year after de-escalation.
• Dupilumab demonstrated good tolerability throughout the treatment period.